Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dosing Protocol
View:
Post by Gman620 on Aug 31, 2022 10:45am

Dosing Protocol

Is there any protocol for continued dosing or is it two treatments and then you wait 450 days to see what happens?  Other drugs have a far greater dosing regimen. How was it decided to proceed with this protocol? It seems that additional treatments could improve results, couldn't it?
Comment by DJDawg on Aug 31, 2022 10:49am
I don't know the history as well as others but I think they got excited and overly confident after the phase 1b patients who were 1 and done. Then later they added a second when reality came back round (1 and done is sweet but not a one sized fits all approach) I think they really wanted to avoid the multiple treatment approach of the other drugs. Once approved I'm sure that you would ...more  
Comment by Oilminerdeluxe on Aug 31, 2022 10:52am
A second dose after 180 days, while the clock is ticking. Yes, it is believed by most here that additional doses could/should/would make results even better. Not sure why it was opted to go with only two treatments per patient, but I am sure others know better.
Comment by Rumpl3StiltSkin on Aug 31, 2022 11:10am
1433 proved very destructive to cancer in vitro. 2 of the 6 in phase 1 have gone into remission from just one optimized treatment.  Yes, more is better considering how in-exact the NMIBC dosimetry can be. Which is why I think once in the clinic perhaps 3 or 4 optimized treatments will be the standard.  The trial design is to 'show off' what 1433 can do. It is about efficacy ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250